Message from the Chair: Digital Intelligence - Pharmaceutical Manufacturing’s Vivianne Arencibia Next Chapter
The pharmaceutical industry has always evolved through the thoughtful application of science and technology. Digital intelligence represents the next chapter in that journey.
For more than two decades, the pharmaceutical industry has invested heavily in digital transformation. Electronic batch records (EBRs), manufacturing execution systems (MESs), laboratory information management systems (LIMs), advanced analytics, and connected manufacturing environments have each fundamentally changed the way we operate.
Yet many organizations continue to face a familiar challenge: Information is abundant, but insight is not always immediate. Data resides across systems, functions, sites, and partners, and critical decisions often require significant effort to gather the right information, understand the context, and determine the best course of action.
AI’s Influence in the Next Pharma Evolution
As products become more complex and supply networks become more interconnected, the ability to make timely, informed decisions is becoming increasingly important. This is where artificial intelligence (AI) is beginning to influence the next phase of our industry’s evolution. Across pharmaceutical manufacturing, we see a shift from digital transformation toward digital intelligence. The distinction is subtle, but important. Digital transformation focuses on creating and connecting information. Digital intelligence focuses on applying that information more effectively.
Organizations are exploring how AI can help identify patterns, recognize emerging risks, improve process understanding, strengthen technology transfer, support quality systems, and enhance operational performance. Although these applications continue to evolve, they share a common objective: helping people make better decisions with greater confidence and speed.
The opportunity extends across the product life cycle. From process development and manufacturing operations to quality investigations, maintenance strategies, and supply chain planning, digital tools are providing insights that were difficult to obtain only a few years ago. One of the most promising developments is the ability to become more proactive. For decades, quality and operational systems have largely been designed to identify and investigate events after they occur. Today, advances in analytics and AI are creating opportunities to detect signals earlier, understand trends more quickly, and respond before issues affect product quality or patient supply.
Ensuring Thoughtful Governance
The potential benefits are significant, but successful application requires thoughtful governance. Pharmaceutical manufacturing operates in an environment in which patient safety, product quality, and regulatory compliance must remain paramount. As organizations adopt AI, they must ensure that outputs are scientifically sound, decisions remain understandable, and appropriate oversight is maintained throughout the system’s life cycle.
Digital tools can strengthen decision-making, but responsibility for those decisions remains with the people who develop, manufacture, and oversee our products.
The discussion often focuses on technical capabilities. Equally important are the governance frameworks that support their use. Data integrity, quality risk management, validation, cybersecurity, and accountability remain essential foundations for adoption. The questions facing leaders are practical. How do we establish confidence in outputs? How do we ensure transparency when decisions are informed by increasingly sophisticated models? How do we integrate these tools into existing quality systems while maintaining appropriate oversight and accountability?
Addressing these questions will require collaboration across disciplines. Quality professionals, engineers, manufacturing teams, data scientists, technology providers, and regulators each bring perspectives that are essential to successful application. Human expertise will remain central throughout this evolution. Pharmaceutical manufacturing depends on scientific judgment, operational experience, and a deep understanding of risk. Digital tools can strengthen decision-making, but responsibility for those decisions remains with the people who develop, manufacture, and oversee our products.
At the same time, we are beginning to see the emergence of adaptive systems that learn from operational data and continuously improve performance. These capabilities create exciting opportunities while introducing new considerations for governance, oversight, and life-cycle management. Establishing common approaches and shared expectations will be important as adoption continues to expand.
From Theory to Practical Implementation
As you will see throughout this issue of Pharmaceutical Engineering®, organizations are already applying these concepts in practical ways. The articles in this issue explore approaches to accelerating decision velocity, establishing governance guardrails for AI, improving technology transfer through digital tools, and managing adaptive systems within GMP environments. Collectively, they demonstrate how digital intelligence is moving from concept to application across pharmaceutical manufacturing.
ISPE has long served as a forum where industry professionals, regulators, and technology experts convene to address emerging challenges and advance good practice. AI presents another opportunity for collaboration. Through the exchange of knowledge, practical experience, and industry guidance, we can help ensure that innovation is implemented responsibly and delivers meaningful value.
Ultimately, success will not be measured by the sophistication of the technology itself. It will be reflected in stronger process understanding, more effective quality systems, more reliable manufacturing operations, and a resilient supply chain capable of meeting patient needs.
The pharmaceutical industry has always evolved through the thoughtful application of science and technology. Digital intelligence represents the next chapter in that journey. As we continue to explore its potential, we have an opportunity to strengthen decision-making, improve resilience, and enhance our ability to deliver safe and effective medicines to patients around the globe.
